NEOLIVER Automated Generation of Dense, Functional and Perfusable Bioprinted Liver Constructs for Transplantation
- Coordinator
- Universiteit Utrecht, Netherlands
- Runs
- 1 January 2025 to 31 December 2028
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €8.0m
- Partners
- 12 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101191649
What the project is doing
In the project's own words, from its summary on CORDIS.
Despite advances in organ transplantation technology, there is still a huge shortage of transplantable organs. Yearly, 25% of patients with end-stage liver disease on the donor waiting list die, emphasizing the need for alternatives to organ donations, such as bioprinting. Bioprinting presents a promising approach for creating organs from scratch, yet, it faces significant hurdles due to technical and biological challenges, combined with lacking standardized procedures and materials.
In NEOLIVER, we will develop large, dense, and vascularized fully functional bioprinted constructs suitable for transplantation. We will achieve this by establishing a GMP-conform manufacturing line for standardized production, ensuring unparalleled quality and safety for future patients. More specifically, by using patient-derived organoids and supporting cells including endothelial cells, we will generate millions of multicellular spheroids as building blocks for bioprinting.
Through laser induced forward transfer (LIFT) bioprinting techniques we will create a vascularized liver construct via precise spatial deposition of spheroids and vessels at high density. By integrating this technology with extrusion-based bioprinted vessels for blood supply, we will generate the world's first autologous bioprinted liver, ready for transplantation. To show the safety and efficacy, we will transplant the bioprinted liver constructs in immune-deficient pigs.
This, combined with a clinical validation plan, upscaling strategy and Health Technology Assessment (including patient acceptance), will prepare the bioprinted liver constructs for first-in-human trials. Thus, NEOLIVER presents a disruptive alternative to donor organs for patients dealing with end-stage liver disease.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Utrecht | Utrecht | Netherlands | Coordinator |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Cellntec Advanced Cell Systems AG | Bern | Switzerland | Associatedpartner |
| Csem Centre Suisse D'electronique Et De Microtechnique SA - Recherche Et Developpement | Neuchatel | Switzerland | Associatedpartner |
| Kugelmeiers AG | Erlenbach | Switzerland | Associatedpartner |
| Amires Sro | Praha | Czechia | Participant |
| Betthera Sro | Hradec Kralove | Czechia | Participant |
| Dwi Leibniz-Institut Fur Interaktive Materialien eV | Aachen | Germany | Participant |
| Phosprint Anonymi Etaireia | Agia Paraskevi Athina | Greece | Participant |
| Fundacion Instituto De Investigacion Sanitaria Aragon | Zaragoza | Spain | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Regen Biomedical BV | Maastricht | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI